Alternative Animal Models for Nanoparticle-Based Drug Delivery: Efficacy and Toxicity Assessment
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: 31 May 2025 | Viewed by 857
Special Issue Editor
Interests: nanotechnology in drug delivery; bioavailability enhancement; nanostructured drug formulations; pharmacokinetics of nanoparticles; nanomedicine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The advancement of nanotechnology in drug delivery systems brings new challenges and opportunities in evaluating the efficacy and safety of nanoparticle-based therapeutics. Traditional animal models, while providing valuable insights, often encounter limitations in fully predicting human responses due to species-specific differences. Moreover, ethical considerations and regulatory demands for reducing animal testing have intensified the need for alternative approaches in preclinical research. This Special Issue, “Alternative Animal Models for Nanoparticle-Based Drug Delivery: Efficacy and Toxicity Assessment”, aims to gather cutting-edge research on innovative models that enhance the translational relevance of preclinical studies in nanomedicine.
Topics of interest include the development and validation of alternative animal models, including zebrafish and invertebrate organisms such as Caenorhabditis elegans, Galleria mellonella, and others. We welcome original research articles and comprehensive reviews on methodologies for nanoparticle toxicity assessment, pharmacokinetics, biodistribution, and therapeutic efficacy using these alternative models. Further, contributions that explore how these models can help in optimizing drug formulation, improving drug targeting, and assessing controlled release systems are highly encouraged.
Additionally, contributions addressing the regulatory perspectives, ethical considerations, and technical challenges associated with these alternative models are encouraged. This Special Issue will also highlight the integration of these models with drug formulation strategies and the application of alternative animal systems to better predict human clinical outcomes in nanoparticle-based therapies. Through this Special Issue, we aim to bridge the gap between preclinical and clinical applications of nanoparticle-based therapies, fostering the development of safer and more effective treatments. We invite researchers from pharmacology, toxicology, bioengineering, and related fields to contribute to this Special Issue and advance the field of nanoparticle drug delivery through innovative and ethically responsible preclinical approaches.
Dr. Rubiana Mara Mainardes
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- alternative animal models
- nanoparticle drug delivery
- nanomedicine
- toxicity assessment
- bioavailability
- in vivo models
- biodistribution studies
- therapeutic efficacy
- pharmaceutical testing
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
